Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Cologne
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06919679CT.gov Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07002216CT.gov BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05615636CT.gov A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05180097CT.gov Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05253495CT.gov Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | — | Recruiting | — | — | — |
NCT04681105CT.gov Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | — | Completed | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03091933CT.gov Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | — | Unknown | — | — | — |
Show 24 more trialsShow fewer
NCT02875067CT.gov Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT02613598CT.gov Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
NCT02181218CT.gov Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | — | Completed | — | — | — |
NCT02208037CT.gov Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | — | Completed | — | — | — |
NCT02280993CT.gov Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | — | Unknown | — | — | — |
NCT01900509CT.gov Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
NCT01619761CT.gov NK Cells in Cord Blood Transplantation | — | Unknown | — | — | — |
NCT01858922CT.gov Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | — | Completed | — | — | — |
NCT01569204CT.gov Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01592370CT.gov An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01453504CT.gov Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01460940CT.gov A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01075321CT.gov Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01116154CT.gov Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01076543CT.gov Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01088763CT.gov Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | — | Terminated | — | — | — |
NCT00994500CT.gov Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | — | Completed | — | — | — |
NCT00791011CT.gov Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | — | Completed | — | — | — |
NCT00439361CT.gov Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00348985CT.gov PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT00302003CT.gov Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00150462CT.gov Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT00096005CT.gov Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Terminated | — | — | — |
NCT00025259CT.gov Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | University of Cologne | P3 | BB · 64 |
| Camustine | VIVUS LLC | P2 | BBB |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vinorelbine Ditartrate | Michael Spinner, MD | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →